Prognose
Analytikernes gennemsnitlige kursmål er 17,68 € (+66,17 %). Medianen er 18,23 € (+71,33 %).
| Køb |
3 |
| Behold |
5 |
| Sælg |
0 |
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
Astria Therapeutics reports strong phase‑1b/2 data for HAE drug Navenibart
The ALPHA‑STAR study of 29 patients showed clear efficacy for Navenibart and a favorable safety profile: median reductions in HAE attack rate of 84–92% over six months and attack‑free rates of 62% and 67% in expanded cohorts. No serious adverse events or study discontinuations were reported; four non‑serious, treatment‑related events resolved quickly. Astria Therapeutics has initiated the phase‑3 ALPHA‑ORBIT study on schedule, with initial results expected in early 2027, and is conducting an open‑label long‑term extension. » Mere på de.investing.com
Astria Therapeutics starts phase‑3 long‑term study ORBIT‑EXPANSE for HAE therapy Navenibart
Astria Therapeutics has started the phase‑3 long‑term study ORBIT‑EXPANSE for Navenibart to prevent hereditary angioedema; participants from the approval‑relevant ALPHA‑ORBIT study can transition. The study includes a fixed dosing phase of at least six months followed by a flexible phase in which patients can receive quarterly or semiannual subcutaneous doses. In parallel, the company is developing the OX40 antibody STAR‑0310 with positive phase‑1a results, and H.C. Wainwright reaffirmed a “Buy” rating and raised the price target to $20.00. » Mere på de.investing.com
Astria reports positive Phase‑1a results for long‑acting OX40 antibody STAR‑0310
Astria Therapeutics reports that STAR‑0310 showed a half‑life of up to 68 days in a Phase‑1a study in healthy volunteers, dose‑proportional increases in concentrations and sustained ex‑vivo cytokine inhibition for 16–20 weeks. The drug was well tolerated at all dose levels; there were no serious treatment‑related events and only seven mild, self‑resolving adverse events. Astria plans an update to its development plans and will present the data at the EAADV congress; analyst targets range from $16 to $49. At a share price of $7.27 the balance sheet shows more cash than debt, but the company remains unprofitable. » Mere på de.investing.com
Virksomhedstal
I det seneste kvartal havde Astria Therapeutics Aktie en omsætning på 601,6 t € og et nettoresultat på -26,96 mio. €
| (EUR) | september 2025 | YoY |
|---|---|---|
| Omsætning | 601,6 t | - |
| Bruttofortjeneste | 601,6 t | - |
| Nettoresultat | -26,96 mio. | - |
| EBITDA | -26,96 mio. | - |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 654,47 mio. € |
Antal aktier | 57,08 mio. |
Højeste/laveste i 52 uger | 12,11 € - 3,24 € |
| Udbytte | Nej |
Beta | 0,02 |
P/E (PE Ratio) | -11,23 |
PEG (PEG Ratio) | 1,37 |
K/I (PB Ratio) | 3,13 |
P/S (PS Ratio) | 1.017,18 |
Virksomhedsprofil
Astria Therapeutics, Inc., et biofarmaceutisk selskab, fokuserer på opdagelse, udvikling og kommercialisering af lægemidler mod sjældne og nicheprægede allergiske og immunologiske sygdomme i USA. Dens vigtigste produktkandidat er STAR-0215, en monoklonal antistofhæmmer af plasma-kallikrein, som er i den prækliniske udviklingsfase til behandling af hereditært angioødem. Selskabet var tidligere kendt som Catabasis Pharmaceuticals, Inc. og skiftede navn til Astria Therapeutics, Inc. i september 2021. Astria Therapeutics, Inc. blev stiftet i 2008 og har hovedsæde i Boston, Massachusetts.
| Navn | Astria Therapeutics Aktie |
| CEO | Jill C. Milne |
| Hjemsted | Boston,
ma USA |
| Websted | |
| Sektor | Materialer |
| Branche | Kemikalier |
| Børsnotering | 25.06.2015 |
| Medarbejdere | 78 |
Tickersymboler
| Børs | Symbol |
|---|---|
NASDAQ | ATXS |